Until now, “hydrochloroquin” is mentioned as a cheap classic malaria drugs . But recently, a study by U.S. scientists has made a conclusion: Hydrochloroquin may delay pancreatic cancer.
The process of self-consumption (autophagy) is often found in cells but at low levels that bring certain benefits. This process allows cells to self-break when the protein cell removal worn or damaged. It is also helping to maintain cell life. When food is scarce, cells break down the protein is not important to their own and eating those protein. Cancer cells also have self-digested process as normal cells. In the harsh conditions, they activates this process, breaks the proteins and eats all those protein to fight, sustain life.
Prof. Dr. Alec Kimmelman and Scientists of Dana-Farber Cancer Institute, have created 3 trial pancreatic cancer models in mice. The first model is associated pancreatic cancer cells in the mouse skin, the first two injections of human pancreatic cancer cells on the right mouse pancreas, No. 3 model for developing pancreatic cancer congenital ( hereditary). Features of pancreatic cancer cells we observed that self-activation process for own lives even in normal conditions (not being the way to the harsh treatment, there is provided nutrition).
When testing three models of pancreatic cancer by hydrochloroquin. The result was unexpected: Hydrochloroquin inhibits activation of target sequences of the cancer cells that is breaking the fight, sustain them. In 3 pancreatic cancer model, the model proved to be a more sensitive hydrochloroquin. All untreated mice died by hydrochloroquin within 140 days, while all mice treated with hydrochloroquin died after 180 days. This means that hydrochloroquin slow the development of the disease, prolong life 40 days (equivalent to 28.5%). Pancreatic cancer model 2 and 3 hydrochloroquin weaker response, particularly in model 3. In model 3, the pancreatic cancer cells is the tough fibrous tissue that surrounds the other, barely giving to promote absorption into effect. However, despite not meeting high as in model 1, at no.3 hydrochloroquin model has achieved a significant effect, extending the life of mice 27 days.
Prof. Kimmelman and Dr.Brian Wolpin have started testing on 36 patients and hope that there will be improvement in the treatment to obtain better results. Accordingly, pancreatic cancer is often difficult to meet with other medicines, including the new drug should be used to increase self-radiation process trigger itself and in combination with standard hydrochloroquin to block the cell’s own-digested pancreatic cancer and get the desired effect. This means to use hydrochloroquin while pancreatic cancer is active.
Doew the anti-malarial drugs hydrochloroquin classic, readily available, inexpensive actually help people fighting pancreatic or not? Waiting and the answer is still ahead.